Article Text

other Versions

A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease

Statistics from

This is a PDF-only article. The first page of the PDF of this article appears below.

PDF extract preview
  • Conflict of interest: J-FC, PR and SJvD have served as consultants to PDL BioPharma, Inc. DWH is supported by a grant from the Netherlands Organisation for Health Research and Development, and has received honoraria and funding for research. MC, HD, TP, MT, and LZ are employees of PDL BioPharma, Inc. None declared by the other authors.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles